Talkmed logo

5G3 - Talkmed Share Price

S$0.435 -0.0  -1.1%

Last Trade - 1:54am

Sector
Healthcare
Size
Small Cap
Market Cap £321.0m
Enterprise Value £273.8m
Revenue £37.0m
Position in Universe 1522nd / 6015
Bullish
Bearish
Unlock 5G3 Revenue
Momentum
Relative Strength (%)
1m -4.75%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
63.2 65.7 68.9 61.4 61.3 75.9 57.1 59.9 +3.7%
+28.3 -4.2 +0.1 -14.3 -9.8 +23.6 -26.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, TalkMed GroupLtd revenues totaled SP$30.7M. Net income totaled toSP$10.7M. Results are not comparable due to year endchange.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 5G3
Graphical History

Revenue

5G3 Revenue Unlock 5G3 Revenue

Net Income

5G3 Net Income Unlock 5G3 Revenue

Normalised EPS

5G3 Normalised EPS Unlock 5G3 Revenue

PE Ratio Range

5G3 PE Ratio Range Unlock 5G3 Revenue

Dividend Yield Range

5G3 Dividend Yield Range Unlock 5G3 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
5G3 EPS Forecasts Unlock 5G3 Revenue
Profile Summary

TalkMed Group Limited is a Singapore-based investment holding company. The Company's principal activities are the provision of medical oncology services and stem cell transplant services. The Company's segments include Oncology services and Stem cells services. Its doctors provide tertiary healthcare services in the fields of medical oncology, stem cell transplant and palliative care to the oncology patients in the private sector in Singapore through Parkway Cancer Centre (PCC). Its clinical functions include attending to patients, examination and administering medical treatment to patients and performing minor outpatient surgical procedures, prescribing medicines and investigations, such as laboratory tests or diagnostic procedures. These clinical functions also include the review of investigation results and follow-up care with the patient. It provides medical oncology services and palliative care services with approximately 13 doctors at over eight clinics.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated September 10, 2013
Public Since January 30, 2014
No. of Shareholders: 930
No. of Employees: 53
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange Singapore Exchange Securities Trading Ltd
Shares in Issue 1,318,054,779
Free Float (0.0%)
Eligible for
ISAs
SIPPs
5G3 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 5G3
Upcoming Events for 5G3
Frequently Asked Questions for Talkmed
What is the Talkmed share price?

As of 1:54am, shares in Talkmed are trading at S$0.435, giving the company a market capitalisation of £321.0m. This share price information is delayed by 15 minutes.

How has the Talkmed share price performed this year?

Shares in Talkmed are currently trading at S$0.435 and the price has moved by -12.87% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Talkmed price has moved by -24.94% over the past year.

What are the analyst and broker recommendations for Talkmed?

Of the analysts with advisory recommendations for Talkmed, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Talkmed is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Talkmed next release its financial results?

Talkmed is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Talkmed dividend yield?

The Talkmed dividend yield is 4.32% based on the trailing twelve month period.

Does Talkmed pay a dividend?

Last year, Talkmed paid a total dividend of 0.02, and it currently has a trailing dividend yield of 4.32%. Looking ahead, Talkmed has not announced an ex-dividend date yet.

When does Talkmed next pay dividends?

Talkmed has yet to annouce their ex-dividend date. The historic dividend yield on Talkmed shares is currently 4.32%.

How do I buy Talkmed shares?

To buy shares in Talkmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Talkmed?

Shares in Talkmed are currently trading at S$0.435, giving the company a market capitalisation of £321.0m.

Where are Talkmed shares listed? Where are Talkmed shares listed?

Here are the trading details for Talkmed:

Country of listing: Singapore
Exchange: SES
Ticker Symbol: 5G3
What kind of share is Talkmed?

Based on an overall assessment of its quality, value and momentum, Talkmed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Talkmed share price forecast 2021?

Shares in Talkmed are currently priced at S$0.435. At that level they are trading at 11.36% discount to the analyst consensus target price of 0.00.

Analysts covering Talkmed currently have a consensus Earnings Per Share (EPS) forecast of 0.02 for the next financial year.

How can I tell whether the Talkmed share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Talkmed. Over the past six months, the relative strength of its shares against the market has been -25.38%. At the current price of S$0.435, shares in Talkmed are trading at 0.24% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Talkmed PE Ratio?

The Talkmed PE ratio based on its reported earnings over the past 12 months is 21.15. The shares are currently trading at S$0.435.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Talkmed?

Talkmed's management team is headed by:

S. Chandra Das - NEC
Peng Tiam Ang - CEO
Kei Siong Khoo - COO
Yih Pin Sitoh - NID
Yock Hian Dan - NID
Jen Howe Lim - NED
Teong Jin Lim - NED
Boon Yong Lee - CFO
Heng Chong Lim - SEC
Lingna Dai - SEC
Who are the major shareholders of Talkmed?

Here are the top five shareholders of Talkmed based on the size of their shareholding:

Ang (Peng Tiam) Individual Investor
Percentage owned: 65.17% (858.9m shares)
Khoo (Kei Siong) Individual Investor
Percentage owned: 7.54% (99.4m shares)
Teo (Cheng Peng) Individual Investor
Percentage owned: 7.45% (98.3m shares)
Lim (Hong Liang) Individual Investor
Percentage owned: 1.33% (17.5m shares)
Lim (Bee Kok) Individual Investor
Percentage owned: 0.35% (4.64m shares)
Similar to 5G3
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.